New Sartorius QbD tool supports faster Raman model building
ambr 15 cell culture system with ambr analysis module showing BioPAT Spectro port, to which a probe for Raman spectrometer is connected.
Unlocking the potential of Raman spectroscopy as a high throughput analytical technique for monitoring cell culture in mini bioreactors.
Sartorius has introduced BioPAT Spectro, a Quality by Design (QbD) tool for use with its ambr automated micro and mini bioreactor systems and with the single-use production bioreactors BIOSTAT STR. The new tool offers access to Raman spectroscopy analysis in high throughput process development, supporting faster Raman model building and accelerating scale-up into commercial manufacturing.
Raman spectroscopy is non-invasive and can measure multiple analytes, making it suitable as a Process Analytical Technologies (PAT) method for process control and monitoring of cell cultures. Off-line approaches to obtain and consolidate enough data to produce a robust Raman model can be time‐consuming and costly. The new BioPAT Spectro Tool, can be retrofitted into ambr 15 cell culture and ambr 250 high throughput systems, and enables quick and simple sampling for integrated at-line analysis of a large number of analytes by Raman spectroscopy in a Design of Experiments (DoE) approach.
Consisting of a multi-use flow cell integrated into the ambr analysis module, BioPAT Spectro in ambr has been successfully demonstrated by major pharmaceutical companies and is compatible with Raman spectrometers from Kaiser Optical Systems and Tornado Spectral Systems. The online Raman spectroscopy data alongside data from the ambr process and selected integrated analysers, is automatically collated by the ambr software and can be easily transferred to SIMCA Multivariate Data Analysis (MVDA) software to build robust Raman models.
One benefit of using BioPAT Spectro with ambr system is that all integrated sampling, sample analysis, data collection, and consolidation is automated, making walk-away Raman spectroscopy analysis in high throughput process development a reality. In addition, one ambr run in 24 mini bioreactors can cover a wide design space, rapidly providing all the data required to build robust Raman models to support QbD, in less than half the time of the conventional benchtop approach.
Developed with scalability in mind, BioPAT Spectro’s flow cell’s Raman probe interface and optical path design is identical across scales so it enables time-saving, automated in-line Raman spectroscopy with Sartorius’ BIOSTAT STR single-use bioreactors. The integrated qualified and ready-to-use single-use spectroscopy port in Flexsafe STR bags for BIOSTAT STR bioreactors will be launched in the near future.
"Unlocking the potential of Raman spectroscopy as a high throughput analytical technique for monitoring cell culture in mini bioreactors has been a key goal of process development scientists for a number of years,” commented Dr Svea Cheeseman, Product Manager Process Analytical Technology at Sartorius. “We are showcasing the BioPAT Spectro at IFPAC and BPI West this year and look forward to discussing with scientists how they can use this new analytical technique with ambr systems to build and utilize robust Raman models, in a workflow which will support their QbD programs, while minimizing resource costs and biologics’ manufacturing timelines,” adds Dr Cheeseman.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...